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Abstract
Asthma is a complex trait for which different strategies have been used to identify its environmental and genetic
predisposing factors. Here, we describe a novel methodological approach to select candidate genes for asthma genetic
association studies. In this regard, the Genes to Diseases (G2D) computational tool has been used in combination with a
genome-wide scan performed in a sub-sample of the Saguenay2Lac-St-Jean (SLSJ) asthmatic familial collection (n=609) to
identify candidate genes located in two suggestive loci shown to be linked with asthma (6q26) and atopy (10q26.3), and
presenting differential parent-of-origin effects. This approach combined gene selection based on the G2D data mining
analysis of the bibliographic and protein public databases, or according to the genes already known to be associated with
the same or a similar phenotype. Ten genes (LPA, NOX3, SNX9, VIL2, VIP, ADAM8, DOCK1, FANK1, GPR123 and PTPRE) were
selected for a subsequent association study performed in a large SLSJ sample (n=1167) of individuals tested for asthma and
atopy related phenotypes. Single nucleotide polymorphisms (n=91) within the candidate genes were genotyped and
analysed using a family-based association test. The results suggest a protective association to allergic asthma for PTPRE
rs7081735 in the SLSJ sample (p=0.000463; corrected p=0.0478). This association has not been replicated in the Childhood
Asthma Management Program (CAMP) cohort. Sequencing of the regions around rs7081735 revealed additional
polymorphisms, but additional genotyping did not yield new associations. These results demonstrate that the G2D tool can
be useful in the selection of candidate genes located in chromosomal regions linked to a complex trait.
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Introduction
Asthma involves genetic and environmental factors in its
development, chronicity and severity [1,2]. Although some of its
underlying mechanisms have been elucidated in recent years,
more work is needed to gain a clearer understanding of genetic
determinants. The mapping of asthma has been one of the most
important areas of human genetics in the last two decades.
According to an overview by Blumenthal (2005), twelve complete
and two incomplete genome scans for asthma have been
published, identifying a total of twenty chromosomal linked
regions to asthma [3]. Discrepancies often appeared between
linkage studies [3–5], leading to the use of standard phenotype
definitions and founder populations as a way to decrease
phenotypic and genetic heterogeneity [6–8].
To date, common strategies have been employed to identify
genes involved in asthma predisposition. Linkage studies followed
by positional cloning identified six genes while association studies
identified over a hundred genes, the majority of these having quite
small effects on asthma susceptibility (see [9,10] for a review).
Here, we describe a novel methodological approach that combines
classical genetic approaches with a computational data-mining
tool. In this regard, a genome-wide scan for asthma and atopy in
families originating from the Saguenay–Lac-St-Jean (SLSJ)
founder population (Northeastern Quebec, Canada) [11–16] has
been combined with the Genes to Diseases (G2D) new
computational tool in the prioritization of asthma candidate genes
[17,18]. G2D performs the selection of the candidates in the
chromosomal regions genetically linked to a disease by highlight-
ing genes whose functions are related to the phenotype of the
disease according to a data mining analysis of the bibliographic
and protein public databases, or according to the genes already
known to be associated with the same or a similar phenotype.
Single nucleotide polymorphisms (SNPs) within the candidate
genes prioritized by the G2D tool have been subsequently used to
conduct an association study with asthma, atopy and allergic
asthma phenotypes in the SLSJ asthma familial collection. The
chromosomal regions around associated SNPs have then been
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the positive association findings has been assessed in the
Childhood Asthma Management Program (CAMP) independent
cohort. The goal was to apply the G2D tool in the search of
genetic determinants associated with a complex trait, using asthma
as a model. This approach led to the hypothesis-driven
identification of ten genes that may not have been selected
otherwise (LPA, NOX3, SNX9, VIL2, VIP, ADAM8, DOCK1,
FANK1, GPR123 and PTPRE). Of these, one positive genetic
association, resisting to corrections for multiple testing, has been
found between the protein tyrosine phosphatase receptor type E
gene (PTPRE) and allergic asthma in the SLSJ sample.
Methods
Subjects
Clinical evaluation and phenotyping criteria of the Saguenay-
Lac-St-Jean (SLSJ) subjects have been described in recent reports
[19–21] and summarized in Table 1. This familial sample is
predominantly composed of probands that reported an onset age
of asthma below 12 years old (81.6% of the probands). The mean
age of onset for the probands is 7 years and the mean age of onset
for the asthmatic family members is 22 years. The entire sample
has been used for the association study while for the genome scan,
the first 79 recruited families, that were available at the time when
the genome scan was performed have been used (n=609
individuals–see supplementary Table S1 for subjects characteris-
tics and studied phenotypes). The Chicoutimi Hospital local ethics
committee approved the study and all subjects provided informed
consent.
Genome Scan
DNAwasextractedforallSLSJparticipants from wholeblood by
using the QIAGEN genomic purification procedure (QIAGEN
Inc., Valencia, CA). Genotyping was completed on 367 autosomal
and 21 X-chromosome microsatellite markers evenly spaced
throughout the genome (average spacing of 9.2 cM). The marker
set is a modification of the Cooperative Human Linkage Centre
Screening Set (http://gai.nci.nih.gov/CHLC/, version 6.0), show-
ing an average heterozygosity of 0.72 in our data set. Each primer
was amplified separately and then pooled into panels of eight
markers and products were interrogated using ABI 3700 sequencers
(Applied Biosystems, Foster City, CA) with a size standard ladder.
Duplicateof two CEPH controlDNAsand one waterwereincluded
in each genotyping plate. In our data set of 195939 autosomal
genotypes, 91.4% of the alleles were called and the proportion of
observed Mendelian error was 1.2%. Linkage of chromosomal
regions with putative genetic risk factors for a given trait was
assessed by evaluatingthe extent of excess sharing of alleles identical
by descent in affected relatives within families. Test statistics are
reported on the LOD scale. Briefly, a multipoint, one-parameter
likelihood ratio test that is robust against incompleteness of marker
data (whenthedescentofallelesina pedigreeisnot fullyknown)was
used [22,23]. We moreover evaluated the specific contribution of
mothersandfatherstothetestoflinkage,tolookforparent-of-origin
effects. The above tests of linkage, linkage through mothers and
linkage through fathers are described in details in [24].
Genes to Diseases (G2D)
The G2D tool has been applied in the two best genome scan
susceptibility regions: 6q26 between markers D6S476 and
D6S305, and 10q26.3 between markers D10S1223 and
D10S1248. We used two of the approaches considered in G2D
[18] to pre-select gene lists in these regions. The first approach
uses a description of the phenotype to point to genes in a region.
This method works with automatically derived relationships
between the disease symptoms (as MeSH C terms) and gene
features (as Gene Ontology or GO terms [25]) that are obtained
from the literature and Entrez gene database (http://www.ncbi.
nlm.nih.gov/). We call this procedure the ‘‘PHENOTYPE’’
method. The second approach consists on automatically finding
genes in a region that are similar to other genes previously
associated to asthma. To do this, G2D measures the semantic
distance between the annotations of the ‘‘known genes’’ and the
annotations of genes in the problem region assigned by homology
searches. We call this procedure the ‘‘KNOWN GENES’’ method.
For details about the algorithm see the G2D web site at http://
www.ogic.ca/projects/g2d_2/ and [17,18].
Association Study
SNP selection. The HapMap database (http://www.
hapmap.org/) has been used to identify SNPs assumed to be
polymorphic in the SLSJ population. TagSNPs were then selected
with the tagger program implemented in the Haploview software
(version 3.32)[26] using an r
2 cutoff of 0.8 and a minor allele
frequency (MAF) over 0.10 to cover each whole gene. SNPs were
also prioritized on their localization (coding or untranslated
regions-see supplementary Table S2). All SNPs are referred using
their reference sequence number (rs#).
SNP genotyping. Eighty SNPs have been genotyped by the
SequenomH matrix-assisted laser desorption/ionization time-of-
flight mass array spectrometer (Sequenom Inc., San Diego, CA)
Table 1. Clinical and phenotypic characteristics of the
Saguenay–Lac-St-Jean association study sample subjects.
Probands
(n=226)
Family members
(n=941)
Male: Female ratio 1: 1.2 1: 1.1
Mean age in years (range) 18 (3–46) 44 (2–96)
Smoking status (n (%))
Never 185 (83.3) 424 (45.8)
Ex-smoker 12 (5.4) 307 (33.2)
Smoker 25 (11.3) 195 (21.0)
FEV1 % of predicted value (SD) * 92.3 (16.3) 94.4 (20.5)
PC20 in mg/ml (SD) { 2.68 (3.59) 10.87 (5.23)
Serum IgE in mg/l (SD) { 233.2 (4.6) 108.0 (4.2)
Number of persons with
subphenotypes (%)
Asthma 1 226/226 (100) 353/935 (37.8)
Atopy P 185/224 (82.6) 468/920 (50.9)
Allergic asthma (Asthma+Atopy) 185/224 (82.6) 239/344 (69.5)
*FEV1=Geometric mean of the force expiratory volume in one second
evaluated for 208 probands and for 683 family members.
{PC20=Concentration of methacholine inducing a 20% fall in FEV1. Geometric
mean and SD were obtained from the log transformed PC20 values. Evaluated
for 186 probands and for 614 family members.
{IgE=Immunoglobulin E serum concentration. Geometric mean and SD were
obtained from the log transformed IgE values. Evaluated for 211 probands and
704 family members.
1Present asthma or past documented clinical history of asthma. The reported
mean age of onset is 7 years among the asthmatic probands and 22 years
among the asthmatic family members.
PDefined as at least one positive response on skin prick testing (wheal diameter
.3 mm at 10 minutes).
doi:10.1371/journal.pone.0002907.t001
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SNP Assay Design software version 3.0 for iPLEX reactions. A
total of 74 assays were designed for a single multiplex reaction.
The assay group file containing the PCR primers and the iPLEX
extension probes can be supplied on request to the corresponding
author. The protocol and reaction conditions are in accordance
with the manufacturer [27]. The genotypes were viewed and
analyzed using the MassARRAY Typer software version 3.4
(Sequenom Inc., San Diego, CA). The ten remaining SNPs (Table
S2) have been genotyped by the TaqManH SNP Genotyping
Assays (Applied Biosystems, Foster City, CA) using the Rotor-
Gene
TM real-time PCR (Corbett Research Ltd, Sydney,
Australia). Protocol and method were supplied by the
manufacturer and PCR conditions were optimized to get a good
cluster separation between different genotypes (see supplementary
Table S3 for PCR conditions). Genotypes were attributed by the
Rotor Gene software using the scatter graph analysis option.
Statistical analysis. Family-based association testing has
been performed with the FBAT software (version 1.7) using an
empirical estimate of the variance [28–30] to correctly account for
linkage. A Sidak correction for multiple testing has been applied
on the p-values accounting for the effective number of
independent phenotypes and SNPs, according to the definition
of Li and Ji [31], as implemented in the SNPSpD program [32]
(see the online supporting Text S1 file for supplementary details).
Parent-specific transmission disequilibrium tests were performed
using sib_tdt from the ASPEX package (http://aspex.sourceforge.
net/). Mendelian errors have been assessed by FBAT and Hardy-
Weinberg equilibrium has been assessed with Haploview software
(version 3.32)[26].
PTPRE Sequencing
Forty unrelated SLSJ subjects (validated with the BALSAC
database [33]) presenting full-fit allergic asthmatic criteria and that
have contributed to the PTPRE association were selected. PTPRE
sequence information was obtained from Ensembl database
(http://www.ensembl.org/index.html, release 46). The sequenc-
ing was divided in six regions that spanned 2.7 kb, starting from
the exon 2 to the exon 4. Oligonucleotides and PCR conditions
are listed in Table S4. Amplification products were purified with
multiscreen PCR plates (Millipore Corporation, Billerica, MA),
sequenced with BigDye terminator v3.1 chemistry following
instructions of the manufacturer and analyzed on a 3100 Genetic
analyzer (Applied Biosystems, Foster City, CA). Sequence analysis
was performed with Codoncode Aligner software (CodonCode
Corporation, http://www.codoncode.com/). The identified SNPs
presenting MAF over 0.05 have been genotyped in the SLSJ
sample using a Sequenom panel and analyzed with FBAT, as
described above. Newly described SNPs have been submitted to
NCBI (http://www.ncbi.nlm.nih.gov/) SNP database.
Replication Study
The PTPRE rs7081735 association has been assessed in the
Childhood Asthma Management Program (CAMP) study [34,35].
This analysis includes the 497 non-Hispanic white children and
their parents for whom adequate DNA was available. The
genotyping of the PTPRE rs7081735 was performed using a
TaqManH SNP Genotyping Assays (Applied Biosystems, Foster
City, CA) (see Table S3 for PCR conditions). Plates were scanned
using the 7900HT Fast Real-Time PCR System (Applied
Biosystems, Foster City, CA) and genotypes were assigned by
the SDS 2.2 software using the scatter graph analysis option. The
Institutional Review Board of the Brigham and Women’s Hospital
(BWH), as well as those of the other CAMP study centers,
approved this study. Informed assent and consent were obtained
from the study participants and their parents to collect DNA for
genetic studies.
Results
Genome Scan
The genome-wide linkage scan analysis revealed at least two
regions showing suggestive evidence for linkage, as well as
differential maternal and paternal contribution (Figure 1). The
two regions are 6q26 for asthma (LOD=1.54, p=0.0038) and
10q26.3 for atopy (LOD=2.82, p=0.00016). In these two
regions, affected sibs tend to share more alleles inherited from
the mothers than from the fathers. The linkage tests through the
mothers reach a LOD of 2.19 (p=0.00074) in 6q26 for asthma
and a LOD of 2.96 (p=0.00011) in 10q26.3 for atopy. The
respective LODs obtained through the fathers at the same loci are
only 0.01 (p=0.40) and 0.58 (p=0.05). Moreover, even though
the 10q region does not show a great strength of linkage with
asthma (LOD=0.57, p=0.051), the asthmatic sibs tend to share
these alleles when received from their mothers (LOD=2.82,
p=0.00016). Each of the two chromosomal regions show LOD
values (either for tests of linkage, or parent-specific LODs, or both)
that are, in order of magnitude, consistent with what has been
defined as «suggestive» for linkage by Lander and Kruglyak [36],
which are expected to occur once per whole genome scan on
average. Because of their great hypothesis generating potential, the
6q26 and 10q26 regions as well as asthma and atopy phenotypes
were selected for the following G2D and association studies.
G2D
We applied the two algorithms PHENOTYPE and KNOWN
GENES to the 6q26 and 10q26.3 regions. For the PHENOTYPE
method, we used the OMIM [37] record 600807 as input,
particularly the MeSH C terms from the MEDLINE references in
OMIM entry 600807 which deals with susceptibility to asthma
and asthma related traits. The most prevailing MeSH C terms are
‘‘Asthma’’ and ‘‘Bronchial Hyperreactivity’’, but the list also
includes ‘‘Hypersensitivity’’, ‘‘Respiratory Hypersensitivity’’ and
‘‘Eosinophilia’’. We thus considered that the terms that refer to
asthma were ‘‘Asthma’’ and ‘‘Bronchial Hyperreactivity’’ and that
the terms that refer to atopy were ‘‘Hypersensitivity’’, ‘‘Respira-
tory Hypersensitivity’’ and ‘‘Eosinophilia’’. The highest scoring
GO terms, associated to these MeSH C terms, describe a variety of
molecular functions and processes that include leukotriene and
interleukin signaling, glutathione metabolism, etc (see header of
supplementary Table S5). We applied this method to the 6q26
region between D6S476 and D6S305, the two markers directly
flanking the linkage peak seen in the region, which corresponds to
the 10.48 MB band between positions 151,685,574 and
162,165,587 of chromosome 6. After discarding candidates that
did not overlap with any known or hypothetical Entrez Gene
sequence, 16 genes remained (see supplementary Table S5-A). A
similar analysis was carried between D10S1223 and D10S1248,
the two markers directly flanking the linkage peak in 10q26.3,
between positions 129,150,822 and 130,982,363 in chromosome
10. In that case, 12 candidates were obtained (see supplementary
Table S5-B). For the KNOWN GENES method, we compiled a
list of genes reported to be associated with asthma and atopy from
the literature [38] and from the Genetic Association Database
GAD [39] (supplementary Table S6). We then extracted the GO
annotation of those genes in Entrez Gene [37]. We derived a
scoring system for the candidates according to the minimal
semantic distance between their GO annotation and the ones from
G2D to Target Asthma Genes
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GO terms such as ‘‘dipeptidyl-peptidase IV activity’’ or ‘‘chemo-
kine receptor binding’’ would score high as candidates. The
method takes into account the hierarchical structure of GO as well
as the specificity of GO terms. In that sense, similarity with more
infrequent terms receive higher scores. For the complete list of GO
terms see the header of supplementary Table S7. We applied the
KNOWN GENES method to both regions 6q26 and 10q26.3,
obtaining 15 and 10 genes, respectively, after filtering out those
candidates that did not overlap with either known or hypothetical
genes (see supplementary Table S7).
Use of a complementary method based on genomic
sequence. We applied the G2D complementary Disease Gene
Prediction (DGP) tool [40] to both genetically linked regions in
order to predict the involvement of genes in inherited disease by
their sequence features. This method analyses the probability of a
gene to be associated with any disease phenotype. Genes with no
associated phenotype and a probability greater than 0.7 were
retained. With this criterion the DGP method identified one
candidate in chromosome 10 (MMP21) and three candidates in
the 6q26 region: TFB1M [MIM:607033], RGS17 [MIM:607191]
and VIP [MIM:192320].
Final list of candidate genes. Genes that received the
higher scores in the pre-selected lists, and those that were pointed
by the two different analyses were preferred, allowing the
construction of a list of 17 candidates (displayed in the Table 2).
Figure 1. Genome scan results summary. Results from the tests of linkage with atopy (top three panels) and asthma (bottom three panels)
reported on the LOD scale. For each phenotype, the top panel shows the results of the test of linkage (excess allele sharing), the middle panel shows
results from the tests of linkage through mothers (excess allele sharing transmitted from mothers) and the bottom panel shows results from the tests
of linkage through fathers (excess allele sharing transmitted from fathers).
doi:10.1371/journal.pone.0002907.g001
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appearance in G2D analyses and on their biological function.
Gene * GeneID/[MIM] Analysis { Gene definition { Gene function {
ARID1B 6q26 57492/[MIM:NA] No AT rich interactive domain
1B (SWI1-like)
Involved in transcriptional activation and repression of select genes
by chromatin remodeling (alteration of DNA-nucleosome topology).
Binds DNA non-specifically.
ESR1 6q26 2099/[MIM:133430] Yes Estrogen receptor 1 Nuclear hormone receptor. The steroid hormones and their
receptors are involved in the regulation of eukaryotic gene
expression and affect cellular proliferation and differentiation in
target tissues.
IGF2R 6q26 3482/[MIM:147280] Yes Insulin-like growth factor 2
receptor
Transmembrane protein with a short cytoplasmic tail containing an
internalization signal. This receptor binds insulin-like growth factor
IGF2.
LPA 6q26 4018/[MIM:152200] No Lipoprotein, Lp(a) Apo(a) is the main constituent of lipoprotein(a). It has a serine
proteinase activity and is able of autoproteolysis. Inhibits tissue-type
plasminogen activator 1.
NOX3 6q26 50508 [MIM:607105] Yes NADPH oxidase 3 NADPH oxidases, such as NOX3, are plasma membrane-associated
enzymes found in many cell types. They catalyze the production of
superoxide by a 1-electron reduction of oxygen, using NADPH as the
electron donor.
SLC22A2 (OCT2) 6q26 6582/[MIM:602608] No Solute carrier family 22
(organic cation transporter),
member 2
Polyspecific transporter of organic cations, mainly expressed in
kidney (luminal membrane of distal tube).
SNX9 6q26 51429/[MIM:605952] No Sorting nexin 9 This gene encodes a member of the sorting nexin family. Members
of this family contain a phox (PX) domain, which is a
phosphoinositide binding domain, and are involved in several stages
of intracellular trafficking.
TFB1M 6q26 51106/[MIM:607033] No Transcription factor B1,
mitochondrial
The transcription of genes from mitochondrial DNA requires a
mitochondrial RNA polymerase and a DNA-binding transcription
factor. Transcription factor B1 (TFB1M) is a part of this transcription
complex and is implied in the rRNA processing.
VIL2 6q26 7430/[MIM:123900] No Villin 2 (ezrin) The cytoplasmic peripheral membrane protein that functions as a
protein-tyrosine kinase substrate in microvilli. Serves as an
intermediate between the plasma membrane and the actin
cytoskeleton. Plays a key role in cell surface structure adhesion,
migration, and organization.
VIP 6q26 7432/[MIM:192320] No Vasoactive intestinal peptid Secreted protein belongs to the glucagon family. It stimulates
myocardial contractility, causes vasodilatation, increases
glycogenolysis, lowers arterial blood pressure and relaxes the
smooth muscle of trachea, stomach and gall bladder.
ADAM8 10q26.3 101/[MIM:602267] No ADAM metallopeptidase
domain 8
Membrane-anchored proteins structurally related to snake venom
disintegrins expressed in granulocyte, monocyte, and macrophage.
Implicated in a variety of biological processes involving cell-cell and
cell-matrix interactions. May be involved in cell adhesion during
neurodegeneration.
CPXM2 10q26.3 119587/[MIM:NA] Yes Carboxypeptidase X,
member 2
Implicated in cell adhesion and proteolysis.
DOCK1 10q26.3 1793/[MIM:601403] Yes Dedicator of cytokinesis 1 Role in signaling from focal adhesions. This gene product binds to
the SH3 domain of CRK protein. It may regulate cell surface
extension and may have a role in the cell surface extension of an
engulfing cell around a dying cell during apoptosis.
FANK1 10q26.3 92565/[MIM:611640] No Fibronectin type III and
ankyrin repeat domains 1
NA
GPR123 10q26.3 84435/[MIM:NA] No G protein-coupled
receptor 123
Orphan receptor : multi-pass membrane protein.
MKI67 10q26.3 4288/[MIM:176741] Yes Antigen identified by
monoclonal antibody Ki-67
Predominantly localized in the G1 phase in the perinucleolar region
and in the nuclear matrix. In mitosis, present on all chromosomes.
Thought to be required for maintaining cell proliferation. Regulation
of progression through cell cycle.
PTPRE 10q26.3 5791/[MIM:600926] Yes Protein tyrosine phosphatase,
receptor type E
PTPs are known to be signaling molecules that regulate a variety of
cellular processes including cell growth, differentiation, mitotic cycle,
and oncogenic transformation.
Genes marked in bold indicate that they have been selected for the association study. NA=Not available.
*Gene symbol, chromosomal location and GeneID number (Entrez Gene identifier in the NCBI database (http://www.ncbi.nlm.nih.gov/)).
{Appears in at least two G2D analyses.
{From NCBI (http://www.ncbi.nlm.nih.gov/) and GeneCards (http://www.genecards.org/) databases.
doi:10.1371/journal.pone.0002907.t002
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ten genes with the best biological potential related to asthma
pathophysiology for genotyping (five in each chromosomal region):
LPA, NOX3, SNX9, VIL2, VIP, ADAM8, DOCK1, FANK1, GPR123
and PTPRE (marked in bold in Table 2).
Association Study
A final panel of 91 SNPs (75 tagSNPs and 16 non-tagSNPs) was
selected among the ten candidate genes (supplementary Table S2).
Of these, four were non-polymorphic, six failed Sequenom
genotyping assays, none presented deviation from Hardy-Wein-
berg equilibrium (p-values .0.001) and one presented more than
two Mendelian errors (Table S2). For the remaining 80 SNPs,
genotypes of individuals with Mendelian errors were considered as
missing data in the FBAT analyses. Genotyping presented a mean
success rate of 99.0% for the Sequenom assays and a mean success
rate of 98.3% for the TaqMan assays. Accounting for the residual
correlation between the tagSNPs, it is estimated that the 80
partially correlated SNPs correspond to an effective number of 59
independent ones [31]. As for the effective number of phenotypes,
simulation indicates that the three studied phenotypes (asthma,
atopy and allergic asthma) correspond to 1.75 effective indepen-
dent ones (see supplementary Text S1 file). Accordingly, the
estimated total effective number of independent tests is 103.25 (59
effective independent SNPs61.75 effective independent pheno-
types). Thus, applying Sidak correction, the p-value threshold of
significance is estimated to be 0.000483.
T h eF B A Ts i n g l em a r k e ra n a l y s e sw e r ep e r f o r m e du n d e ra n
additive genetic model for each SNP and the three studied
phenotypes. For the sake of brevity, only results showing a p-value
under 0.05 before correction for multiple testing for one or more
phenotypes are presented in Table 3. For the asthma phenotype,
minor alleles LPA_rs12175867C, GPR123_rs11101913T,
GPR123_rs11101932T and GPR123_rs12257731A were overtrans-
mitted to the asthmatic probands, suggesting a susceptibility effect of
these alleles for asthma (0.0085,p,0.047). Inversely, minor alleles
DOCK1_rs1051039G, PTPRE_rs4369314A and PTPRE_
rs7081735G were undertransmitted to the asthmatic probands,
suggesting a protective effect of these alleles for asthma
(0.010,p,0.049). For the atopy phenotype, only
ADAM8_rs11101672G and PTPRE_rs7081735G minor alleles have
beenundertransmitted to the atopic probands, suggestinga protective
effect (p=0.039 and 0.037, respectively). Finally, for the allergic
asthma phenotype, minor alleles LPA_rs12175867C, GPR123_
rs11101913T, GPR123_rs11101932T and GPR123_rs12257731A
were overtransmitted to the allergic asthmatic probands, suggesting a
susceptibility effect of these alleles for allergic asthma
(0.035,p,0.041). Inversely, minor alleles ADAM8_rs11101672G,
GPR123_rs11101916A, GPR123_rs761777G, PTPRE_rs11016002A,
PTPRE_rs4002572CandPTPRE_rs7081735Gwereundertransmitted
to the allergic asthmatic probands, suggesting a protective effect of these
alleles for allergic asthma (0.000463,p,0.037). None of the SNPs
reported above showed a significantly greater extent of transmission
distortion from mothers than from fathers, thus not providing insights to
the observed parental distortions seen in the linkage results (not shown).
PTPRE Sequencing
PTPRE rs7081735 shows the strongest association to allergic
asthma (p=0.000463) and is the only SNP shown to be significant
after multiple testing correction (corrected p=0.0478). We thus
sequencedstrategic genomic regionsaroundthers7081735,including
coding regions in order to identify causal mutation. Figure 2 shows
the PTPRE sequenced regions, the rs7081735 localization and the
nine identified variants (diamonds), including four novel ones
(c.86172A.G, c.140901G.A, c.140903G.A and c.141102C.T)
(Table 4). It is worth to note that any of these identified
polymorphisms may affect either PTPRE isoforms. A family-based
association analysis has been performed between the three studied
phenotypes and variants presenting a MAF over 0.05 that were not
included in the first genotyping panel, which was the case for four of
the nine identified variants (rs7911506, c.86172A.G, rs7895103 and
c.140901G.A). Only rs7895103 showed a modest association with
asthma, at a level that does not provide additional insights (p=0.013,
compared to p=0.000463 for rs7081735).
Table 3. Significant Family-Based Association Test (FBAT) results between the ten G2D candidate genes studied SNPs and asthma,
atopy and allergic asthma phenotypes under an additive genetic model.
Gene SNP
Base
change MAF Asthma Atopy Allergic Asthma
NZ P NZ P NZ P
LPA rs12175867 T.C 0.16 81 1.98 0.0474 68 1.94 0.0530 71 2.04 0.0412
ADAM8 rs11101672 C.G 0.23 95 21.76 0.0784 79 22.06 0.0390 82 22.12 0.0340
DOCK1 rs1051039 C.G0 . 4 1 1 1 7 21.97 0.0486 101 20.72 0.4739 103 20.48 0.6336
GPR123 rs11101913 C.T 0.29 112 2.63 0.0085 94 1.81 0.0707 97 2.04 0.0412
rs11101916 G.A 0.18 95 21.79 0.0731 73 21.31 0.1916 80 22.16 0.0308
rs11101932 C.T 0.15 80 2.26 0.0240 60 1.74 0.0816 66 2.26 0.0397
rs761777 A.G0 . 2 9 1 1 3 21.30 0.1948 92 21.00 0.3152 99 22.31 0.0209
rs12257731 G.A 0.12 77 2.15 0.0314 60 1.65 0.0995 65 2.11 0.0353
PTPRE rs11016002 A.T0 . 3 5 1 1 3 21.04 0.2983 89 21.33 0.1836 93 22.47 0.0136
rs4369314 G.A 0.21 96 22.57 0.0101 81 21.65 0.0999 83 21.67 0.0958
rs4002572 C.T0 . 4 5 1 1 3 21.61 0.1067 86 21.03 0.3047 93 22.09 0.0367
rs7081735 A.G0 . 3 2 1 1 1 22.23 0.0256 88 22.09 0.0371 91 23.50 0.000463
Abbreviations used: SNP=Single nucleotide polymorphism, MAF=Minor allele frequency, N=Number of families contributing to the statistic, Z=Z score, P=p-value
(significance threshold of 0.000483; p-values under are marked in bold).
doi:10.1371/journal.pone.0002907.t003
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Considering that the PTPRE rs7081735 association to allergic
asthma is the strongest in the SLSJ sample, we evaluated it in an
independent familial cohort, the Childhood Asthma Management
Program (CAMP) [34]. The genotyping completion rate was 96%
and no discordance was observed upon repeat genotyping of two
random plates. The minor allele frequency was 0.33 and was in
Hardy-Weinberg equilibrium (p=0.90). Family-based association
showed no significant association for asthma or atopy phenotypes
(data not shown). However, to ensure that the selection of the
CAMP study for the replication is appropriate and to demonstrate
that the association found could result from a childhood subset of
asthma instead of an adulthood one, we stratified the SLSJ
association analyses considering only the probands that reported
an asthma age of onset below 12 years old. Thus, the positive
association found for PTPRE rs7081735 and allergic asthma
(p=0.000463, Table 3) remains significant when considering only
those probands (Family number=74; Z for the minor
Figure 2. PTPRE gene sequenced regions and identified SNPs scaled location. The black thick boxes above the gene define its sequenced
parts, which are identified by the same numbers used in the Table 4, in which exact chromosomal positions are available. Studied SNPs are
represented below the gene. The TagSNPs correspond to an asterisk (*) and the SNPs identified by sequencing correspond to a diamond (e). All
PTPRE numbers for the discovered SNPs are based on the mRNA sequence NM_006504 (variant 1, receptor form) and from the NCBI (http://www.ncbi.
nlm.nih.gov/) SNP database (build 127). Image source: HapMap (www.hapmap.org/) October 2007 (Genome Browser, http://genome.ucsc.edu/,
version 1.69); modified according to our study design.
doi:10.1371/journal.pone.0002907.g002
Table 4. PTPRE sequenced regions and characteristics of identified SNPs.
Sequenced regions [bp] * Identified SNP { Base change MAF (SLSJ) { MAF (CEU) 1 SNP location *
1 [75542–75977] No SNPs found
2 [85761–86205] rs7911506 C.T 0.49 0.296 Intron 2
c.86172 A.G A.G 0.31 NA Intron 2
3 [88011–88457] rs4369314 G.A 0.17 0.192 Intron 2
4 [92004–92507] rs7081735 A.G 0.47 0.342 Intron 2
rs7895103 T.C 0.05 0.217 Intron 2
5 [134156–134591] No SNPs found
6 [140684–141152] rs4262642 C.A 0.19 0.25 Intron 3
c.140901 G.A G.A 0.40 NA Intron 3
c.140903 G.AG .A 0.03 NA Intron 3
c.141102 C.TC .T 0.03 NA Intron 4
SNPs marked in bold have been genotyped and analyzed.
Abbreviations used: bp=base pairs, SNP=single nucleotide polymorphism, MAF=Minor allele frequency, SLSJ=Saguenay-Lac-St-Jean, CEU=CEPH Utah residents with
ancestry from northern and western Europe, NA=Not available.
*Base pair numbering according to NCBI (http://www.ncbi.nlm.nih.gov/) genome assembly (Build 36.2).
{If known from NCBI SNP and Ensembl (http://www.ensembl.org/index.html) databases, reported by the NCBI rs#.
{Calculated on 39 individuals originating from the SLSJ population.
1Obtained from the HapMap international project database (http://www.hapmap.org/).
doi:10.1371/journal.pone.0002907.t004
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power due to the stratified analysis, this comparison allowed to
assume that the association found for PTPRE is probably more
related to a childhood asthma, comforting the choice of the
CAMP cohort as a replication study.
Discussion
This study proposes a novel approach for the selection of
candidate genes for asthma association studies using the
computational G2D tool to find genetic determinants for this
disease. Based on a genome-wide scan performed in an asthmatic
familial sample from the SLSJ founder population, we selected the
two best-linked regions (6q26 and 10q26.3) and applied the G2D
data mining approach [17,18] to identify ten candidate genes for
an association in the SLSJ sample. Among these, five (LPA,
ADAM8, DOCK1, GPR123 and PTPRE) presented modest
associations with asthma, atopy or allergic asthma. After
corrections for multiple testing, only the PTPRE rs7081735
association to allergic asthma remained significant. These findings
demonstrate that the G2D tool can be useful in the selection of
candidate genes for asthma genetic studies.
Because the PTPRE association to allergic asthma remained
significant after correction for multiple testing, we sequenced
strategic regions around the rs7081735, aiming to find the causal
mutation. Sequencing allowed the identification of five known and
four novel variants. Testing four SNPs with MAF .0.05 did not
identify additional associated SNPs with asthma or atopy related
phenotypes in the SLSJ sample. Thus, the rs7081735, located in
the 59 untranslated region, could be the causal variant, or be in
linkage disequilibrium with an unknown causal mutation.
PTPRE is a member of the protein tyrosine phosphatase (PTPs)
family, which includes genes that are important regulators of signal
transduction pathways involved in various cellular processes such
as control of metabolic pathways, cellular adhesion, cell cycle
progression and immune response [41,42]. PTPRE encodes two
different isoforms, cytoplasmic and transmembrane [43], based on
its different promoters [44]. PTPs receptors participate in
transmembrane signaling and cellular adhesion processes, whereas
intracellular PTPs take part in signal transduction within the cell
[45]. For example in mice, PTPe-deficient macrophages present
abnormalities in the regulation of the respiratory burst and the
production of cytokines in response to bacterial lipopolysaccha-
ride, suggesting a role of the PTPe isoform in inflammation as well
as in host defense [46]. However, PTPRE has been shown to be
highly expressed in peripheral human monocytes and granulo-
cytes, and antigen-receptor stimulation induces the expression of
PTPRE in activated lymphocytes [47]. These observations and our
finding suggest a protective effect of PTPRE in allergic asthma,
and lead us to hypothesize that this potential protective role could
involve the leukocyte cellular processes in the limitation of lung
inflammation following an allergen sensitization. Further work is
needed to define the PTPRE possible role in asthma pathophys-
iology.
The PTPRE rs7081735 association has been evaluated in the
independent CAMP cohort. Results showed no positive associa-
tion for asthma and atopic phenotypes. Taking into account that
the SLSJ and the CAMP studies are both family-based designed,
well powered [48,49] and presenting a childhood onset asthma,
the PTPRE association lack of replication in the CAMP study can
be explained by other reasons: natural variability of asthma history
[50,51], differences of proband mean age between samples (SLSJ
mean age of 18, and CAMP mean age of 8, respectively),
differences in the genetic background of the two populations [52]
(SLSJ individuals descend predominantly from French European
founders [11–16] whereas CAMP individuals come from a white
North-American admixed population), or population specific
gene-gene and gene-environment interactions [52]. Based on
these observations, we conclude that the PTPRE rs7081735
association to allergic asthma is more penetrant in the SLSJ
population, possibly resulting from an interaction with others
genes and/or environmental factors that are more common in this
founder population.
In summary, this study demonstrates that the G2D tool can be
useful in the prioritization of candidate genes for a complex disease
as it allowed us to find a novel asthma genetic association with the
PTPRE gene in the SLSJ familial asthma sample. This association
represents a potential protective factor for asthma pathogenesis, as
it is more likely related to a childhood onset asthma. The present
genetic study is an example of how the combination of different
methodological approaches can be relevant to target asthma
genetic determinants and to motivate further genetic and
functional investigations.
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